NASDAQ:CHEKCheck Cap Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Check Cap Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.59 +0.02 (+3.94 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$0.56Now: $0.59▼$0.6450-Day Range$0.53MA: $0.56▼$0.6952-Week Range$0.44Now: $0.59▼$2.37Volume6.03 million shsAverage Volume1.72 million shsMarket Capitalization$6.49 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCheck Cap has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Check Cap has a potential upside of 408.1% from its current price of $0.59.Amount of Analyst CoverageCheck Cap has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesCheck Cap has received 346 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCheck Cap has received 255 “underperform” votes. (Add your “underperform” vote.)Community SentimentCheck Cap has received 57.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Check Cap and other stocks. Vote “Outperform” if you believe CHEK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHEK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCheck Cap does not currently pay a dividend.Dividend GrowthCheck Cap does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Check Cap insiders have not sold or bought any company stock. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Check Cap are expected to grow in the coming year, from ($0.57) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Check Cap is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Check Cap is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCheck Cap has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry X-ray apparatus & tubes Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHEK Previous Symbol CUSIPN/A CIK1610590 Webwww.check-cap.com Phone972-4830-3401Debt Debt-to-Equity RatioN/A Current Ratio3.69 Quick Ratio3.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.88 per share Price / Book0.15Profitability EPS (Most Recent Fiscal Year)($1.73) Net Income$-13,840,000.00 Net MarginsN/A Return on Equity-151.94% Return on Assets-115.54%Miscellaneous Employees56 Outstanding Shares10,997,000Market Cap$6.49 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:CHEK Rates by TradingView Receive CHEK News and Ratings via Email Sign-up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter. Check Cap (NASDAQ:CHEK) Frequently Asked Questions How has Check Cap's stock been impacted by COVID-19 (Coronavirus)? Check Cap's stock was trading at $1.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CHEK shares have decreased by 55.3% and is now trading at $0.5904. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Check Cap? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Check Cap in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Check Cap. When is Check Cap's next earnings date? Check Cap is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Check Cap. How were Check Cap's earnings last quarter? Check Cap Ltd (NASDAQ:CHEK) announced its quarterly earnings results on Wednesday, May, 27th. The medical research company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.02. View Check Cap's earnings history. When did Check Cap's stock split? How did Check Cap's stock split work? Check Cap's stock reverse split on Wednesday, April 4th 2018. The 1-12 reverse split was announced on Wednesday, April 4th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 3rd 2018. An investor that had 100 shares of Check Cap stock prior to the reverse split would have 8 shares after the split. What price target have analysts set for CHEK? 2 Wall Street analysts have issued 12-month target prices for Check Cap's stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Check Cap's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 408.1% from the stock's current price. View analysts' price targets for Check Cap. Has Check Cap been receiving favorable news coverage? News headlines about CHEK stock have trended negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Check Cap earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news about Check Cap. Who are some of Check Cap's key competitors? Some companies that are related to Check Cap include GeneNews (GEN), Tissue Regenix Group (TRX), Delcath Systems (DCTH), Konekt (KKT), Nova Leap Health (NLH), Eyegate Pharmaceuticals (EYEG), Oragenics (OGEN), Cyclerion Therapeutics (FBRX), Inspiration Healthcare Group (IHC), KDA Group (KDA), OHR Pharmaceutical (OHRP), AzurRx BioPharma (AZRX), Bionomics (BNO), Oneview Healthcare (ONE) and MGC Pharmaceuticals (MXC). View all competitors. What other stocks do shareholders of Check Cap own? Based on aggregate information from My MarketBeat watchlists, some companies that other Check Cap investors own include Alibaba Group (BABA), Navios Maritime Partners (NMM), New Residential Investment (NRZ), Heat Biologics (HTBX), Novavax (NVAX), Magnegas Applied Tchnlgy Sltns (MNGA), Genocea Biosciences (GNCA), Intel (INTC), Paypal (PYPL) and Sorrento Therapeutics (SRNE). Who are Check Cap's key executives? Check Cap's management team includes the following people: Mr. Alex Ovadia, CEO & Director (Age 57)Dr. Yoav Kimchy, Founder & Chief Technology Officer (Age 58)Ms. Mira Rosenzweig, Chief Financial Officer (Age 47)Mr. Lior Torem, Chief Financial Officer (Age 49)Boaz Shpigelman, VP of R&D (Age 47) When did Check Cap IPO? (CHEK) raised $13 million in an initial public offering on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group served as the underwriters for the IPO and Feltl and Company was co-manager. What is Check Cap's stock symbol? Check Cap trades on the NASDAQ under the ticker symbol "CHEK." How do I buy shares of Check Cap? Shares of CHEK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Check Cap's stock price today? One share of CHEK stock can currently be purchased for approximately $0.59. How big of a company is Check Cap? Check Cap has a market capitalization of $6.49 million. The medical research company earns $-13,840,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Check Cap employs 56 workers across the globe. What is Check Cap's official website? The official website for Check Cap is www.check-cap.com. How can I contact Check Cap? Check Cap's mailing address is 29 ABBA HUSHI AVE. P.O.BOX 1271, ISFIYA L3, 3009000. The medical research company can be reached via phone at 972-4830-3401 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
